

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2010291208 B2**

(54) Title
Polypeptides having oxidoreductase activity and their uses

(51) International Patent Classification(s)
C07D 307/50 (2006.01) **C12N 9/02** (2006.01)
C11D 3/386 (2006.01) **C12P 7/44** (2006.01)

(21) Application No: **2010291208** (22) Date of Filing: **2010.09.02**

(87) WIPO No: **WO11/026913**

(30) Priority Data

(31) Number	(32) Date	(33) Country
09172555.6	2009.10.08	EP
09169227.7	2009.09.02	EP

(43) Publication Date: **2011.03.10**

(44) Accepted Journal Date: **2015.04.09**

(71) Applicant(s)
Purac Biochem B.V.

(72) Inventor(s)
Ruijssenaars, Harald Johan;Wierckx, Nick Johannes Petrus;Koopman, Frank Wouter;Straathof, Adrianus Johannes Jozef;De Winde, Johannes Hendrik

(74) Agent / Attorney
Phillips Ormonde Fitzpatrick, 367 Collins Street, Melbourne, VIC, 3000

(56) Related Art
GENBANK Accession Number CP001052, 7 May 2008
UNIPROT Accession Number B2JSZ0, 10 June 2008
UNIPROT Accession Number B2T4R9, 1 July 2008
US 2007/0243594 A1 (GUPTA et al) 18 October 2007

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 March 2011 (10.03.2011)

PCT

(10) International Publication Number
WO 2011/026913 A1

(51) International Patent Classification:

C07D 307/50 (2006.01) **C12N 9/02** (2006.01)
C11D 3/386 (2006.01) **C12P 7/44** (2006.01)

(74) Agents: **KLEIBORN, Paul Erik** et al.; DSM Intellectual Property, Delft Office (600-0240), P.O. Box 1, NL-2600 MA Delft (NL).

(21) International Application Number:

PCT/EP2010/062896

(22) International Filing Date:

2 September 2010 (02.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09169227.7 2 September 2009 (02.09.2009) EP
09172555.6 8 October 2009 (08.10.2009) EP

(71) Applicant (for all designated States except US): **DSM IP ASSETS B.V.** [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RUIJSSENAARS, Harald Johan** [NL/NL]; De Kievit 120, NL-3972 PL Driebergen-rijnsenburg (NL). **WIERCKX, Nick Johannes Petrus** [NL/NL]; W.H. van Leeuwenlaan 92, NL-2613 ZG Delft (NL). **KOOPMAN, Frank Wouter** [NL/NL]; Bernadottelaan 86, NL-3527 GB Utrecht (NL). **STRAATHOF, Adrianus Johannes Jozef** [NL/NL]; Zuidwal 7, NL-2611 MZ Delft (NL). **WINDE, DE, Johannes, Hendrik** [NL/NL]; Saffraanweg 51, NL-2215 WC Voorhout (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GI, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))



WO 2011/026913 A1

(54) Title: POLYPEPTIDES HAVING OXIDOREDUCTASE ACTIVITY AND THEIR USES

(57) Abstract: The invention relates to a polypeptide having oxidoreductase activity which comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having 45% or more sequence identity with the sequence of SEQ ID NO: 3. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (FDCA) or production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid).

POLYPEPTIDES HAVING OXIDOREDUCTASE ACTIVITY AND THEIR USES

Field of the invention

The invention relates to polypeptide having oxidoreductase activity and to polynucleotide sequences comprising a gene that encodes the polypeptide. The invention further relates to the production of 2,5-Furan-dicarboxylic acid (FDCA). Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these polypeptides, which may also be used for biotransformation of hydroxymethylfurfural (HMF) to FDCA.

Background of the invention

2,5-Furan-dicarboxylic acid (FDCA) has large potential to become a bio-based alternative for terephthalate in the production of polyesters such as PET. As such and for other reasons FDCA was identified as one of the Top-12 priority chemicals in the DOE report on Top Value-Added Chemicals from Biomass (Top Value-Added Chemicals from Biomass, Volume I - Results of screening for potential Candidates from Sugars and Synthesis gas, Department of Energy (USA), 2004). This compound may be obtained by oxidation of 5-hydroxymethylfurfural (HMF), which can be produced by heating hexose sugars under acid conditions. The DOE report discloses on page 27, some potential utilities for FDCA. These include a role as substrate for the production of succinic acid, 2,5-bis(aminomethyl)-tetrahydrofuran, 2,5-dihydroxymethyl-tetrahydrofuran, 2,5-dihydroxymethylfuran and 2,5-furandicarbaldehyde. Although the production of FDCA by chemical oxidative dehydration of C6 sugars and uses of FDCA are well described and poses technical barriers indicated in table 13 on page 26, for biotransformation - possibly enzymatic conversions – the position was unknown.

A process for the enzymatic preparation of FDCA is given in WO2009/023174. In this disclosure, a hydroxymethylfurfural species is oxidised with a chloroperoxidoreductase and hydrogen peroxide oxidised products having a carboxylic acid group at the C1 position of the hydroxymethylfurfural, in particular formylfuran carboxylic acid or FFCA. Results are e.g. shown in Figure 1. In another embodiment, HMF is contacted with an oxidoreductase in the presence of an oxidizing substrate, whereby HMF is oxidized to at least one of diformylfuran or formylfuran carboxylic acid.

Disadvantages of the described process in WO2009/023174 are that the reaction requires hydrogen peroxide and that the product formed is a mixture of FDCA with two

contaminating byproducts, hydroxymethylfuran carboxylic acid (HmFCA) and formylfuran carboxylic acid (FFCA). Consequently the yield of FDCA from HMF is reduced and additional recovery steps are needed to obtain FDCA in a substantially purified form.

In database EBI, Uniprot B2T4R9, a sequence of 577 aminoacids was identified that was inferred from homology as Glucose-Methanol-Choline oxidoreductase in the "complete sequence of chromosome 1 of *Burkholderia phytofirmans* PsJN."

In database EBI, Uniprot B2JSZ0, a sequence of 576 aminoacids was identified that was inferred from homology as Glucose-Methanol-Choline oxidoreductase in the "complete sequence of plasmid 1 of *Burkholderia phymatum* STM815."

In Deurzen, M.P.J. et al, J. Carbohydrate Chemistry 16(3), 299-309 (1997), the chloroperoxidase-catalysed oxidation of 5-Hydroxymethylfurfural is disclosed. The reaction proceeds with 60-74% selectivity to furan-2,5-dicarboxaldehyde (FDC). Byproducts were 5-hydroxymethyl-2-furancarboxylic acid (HFCA) and 5-formylfuran-2-carboxylic acid (FFCA).

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or group thereof.

Summary of the invention

An aspect of the invention is to provide an oxidoreductase that can use molecular oxygen for redoxreactions. Another aspect is to provide an oxidoreductase that has broad reaction spectrum. Another aspect is to provide an oxidoreductase that has high regio-specificity. A further aspect of the invention is to provide a process for the production of FDCA wherein substantial amount of by-products can be avoided. A further aspect of the invention is to provide a process for the production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid) wherein substantial amount of by-products can be avoided. One or more of these aspects are attained according to the invention.

The present invention provides polynucleotides encoding polypeptides having the oxidoreductase activity. Polynucleotides of the invention typically encode a polypeptide having oxidoreductase activity, in particular HmfH oxidoreductase activity.

According to the invention, there is thus provided a polypeptide having
5 oxidoreductase activity which comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having 45% or more sequence identity or more with the sequence of SEQ ID NO: 3.

These oxidoreductase polypeptides offer an enzymatic alternative to chemical
10 oxidation routes to produce the value added compound FDCA, allowing mild reaction conditions (30°C, pH 7) and producing less waste. The oxidoreductase is a true oxidase, i.e. only molecular oxygen is required for the oxidation reaction omitting the requirement for regeneration of expensive cofactors. The enzyme offers broad reaction specificity and regio-specificity, oxidizing both alcohol and aldehyde groups to eventually carboxylic
15 acid, irrespective whether these groups are on the C2 or C5 position of the furan backbone.

Also provided according to the invention is a vector, such as an expression vector, incorporating a polynucleotide sequence of the invention and a cell comprising a polypeptide, a polynucleotide or a vector, according to the invention.

20 The invention further provides a method for the preparation of a polypeptide having oxidoreductase activity, which method comprises cultivating a cell of the invention under conditions which allow for expression of said polypeptide and, optionally, recovering the expressed polypeptide and a polypeptide obtainable by such a method.

Another embodiment of the invention relates to an integrated process for the
25 production of FDCA from fructose-(en)rich(ed) feed streams using a robust whole-cell biocatalyst.

Another embodiment of the invention provides an isolated polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 70% or more sequence identity with SEQ ID NO: 3.

30 Another embodiment of the invention provides an isolated polynucleotide which comprises: (a) the nucleotide sequence set out in SEQ ID NO: 4; (b) a nucleotide sequence encoding a polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 3; (c) a fragment of a nucleotide sequence as defined in (a) or (b) which is at least

about 100 nucleotides in length; or (d) a nucleotide sequence which is the reverse complement of a nucleotide sequence as defined in (a), (b) or (c).

Another embodiment of the invention provides process for the production of 2,5-furandicarboxylic acid (FDCA), wherein one or more furanic precursor of FDCA is converted to FDCA, by reaction with an oxidant in the presence of an oxidoreductase catalyst and optionally one or more coenzyme, wherein the oxidoreductase catalyst comprises a polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 45% sequence identity with SEQ ID NO: 3.

Another embodiment of the invention provides process for the production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid) wherein one or more furanic precursor of HMF acid is converted to HMF acid by reaction with an oxidant in the presence of an oxidoreductase catalyst and optionally one or more coenzyme cofactor, wherein the oxidoreductase catalyst comprises a polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 45% sequence identity with SEQ ID NO: 3.

Brief description of the figures

Fig. 1: Reaction scheme of oxidations catalysed by the HmfH oxidoreductase

Fig. 2: Plasmid map of HmfH expression vector pJT'hmfH. Ptac', *tac* promotor; rep, gene encoding the pRO1600 replication protein; gmR, gentamicin resistance gene; bla, beta-lactamase; pRO1600-ori, origin of replication for *P. putida*; pUC ori, origin of replication for *E. coli*.

Fig. 3: Schematic representation of the genetic organization of the furfural and HMF metabolic genes in *C. basilensis* HMF14 (A) and other species (B) that were identified as potential furfural and / or HMF utilizers

Fig. 4: Formation of FDCA, HMF-alcohol (H-oh) and HMF-acid (H-acid) from HMF in

crude cell extract of *P. putida* S12 pJT'hmfH.

Fig. 5: Formation of HMF acid and FDCA in a fed-batch culture of *P. putida*_pJT'hmfH. The left-hand arrow indicates the start of the HMF feed; the right-hand arrow indicates the addition of glycerol to the feed.

Fig. 6: Formation of HMF acid and FDCA in a fed-batch culture of *P. putida*_pJT'hmfH. The arrow indicates the start of the combined HMF and glycerol feed.

Figure 7a: Concentrations of HMF acid, FDCA and biomass in the fed-batch fermentation of example VIII. 7b: feed rates of glycerol and HMF in the fed-batch fermentation of example VIII.

Brief description of the sequence listing

SEQ ID NO: 1 sets out the DNA sequence of primer FN23: 5'-CGGAATTCCACATGACAAGGGGAGACCG-3'. Underlined sequence indicates an EcoRI restriction site;

SEQ ID NO: 2 sets out the DNA sequence of primer FN24; 5'-CGGAATTCGCTTCGGTCTTCAACTCGGATG-3'. Underlined sequence indicates an EcoRI restriction site;

SEQ ID NO: 3 sets out the amino acid sequence of HmfH

SEQ ID NO: 4 sets out the coding sequence of *hmfH*;

Detailed description of the invention

Throughout the present specification and the accompanying claims, the words "comprise" and "include" and variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusively. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to one or at least one) of the grammatical object of the article. By way of example, "an element" may mean one element or more than one element.

Broad reaction spectrum herein means the oxidoreductase can act as catalyst
5 for the many different substrates e.g. HMF, HMFacid, HMF alcohol, furfural, furfuryl alcohol. Regio-specificity means it only oxidizes specific C-atoms.

Oxidoreductase polypeptide

A polypeptide according to the invention having oxidoreductase activity
10 comprises the amino acid sequence set out in SEQ ID NO: 3 or an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, or a variant polypeptide thereof having at least 45% sequence identity with the sequence set out in SEQ ID NO: 3.

In one embodiment the variant nucleic acid molecule comprises a nucleotide sequence encoding a protein, comprising a substantially homologous nucleotide
15 sequence of at least 66%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,

96%, 97%, 98%, 99% or more homologous to the nucleotide sequence shown in SEQ ID NO: 4. In another embodiment the variant protein comprises a substantially homologous amino acid sequence of at least 45%, 50%, 55%, 60%, 65%, 70%, 75%,
20 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3.

An embodiment of the invention is a polynucleotide which comprises: (a) the nucleotide sequence set out in SEQ ID NO: 4; (b) a nucleotide sequence which hybridizes selectively with a polynucleotide being the reverse complement of SEQ ID NO: 4; (c) a nucleotide sequence having at least 66% sequence identity or more with the
25 nucleotide sequence of SEQ ID NO: 4; (d) a fragment of a nucleotide sequence as defined in (a), (b) or (c) which is at least about 100 nucleotides in length; (e) a sequence which is degenerate as a result of the genetic code to a sequence as defined in any one of (a), (b), (c) or (d); (f) a nucleotide sequence which is the reverse complement of a nucleotide sequence as defined in (a), (b), (c), (d) or (e), or encodes a polypeptide; and
30 to the relating polypeptides.

One embodiment is a nucleic acid construct comprising the polynucleotide, wherein GC content may be 56% or more, 58% or more, or from 58-65%. Further embodiment is a vector incorporating the polynucleotide sequence or a nucleic acid construct.

The terms "homology", "sequence identity" and the like are used interchangeably herein. For the purpose of this invention, it is defined herein that in order to determine the degree of sequence identity shared by two amino acid sequences or by two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps
5 can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). Such alignment may be carried out over the full lengths of the sequences being compared. Alternatively, the alignment may be carried out over a shorter comparison length, for example over about 20, about 50, about 100 or more nucleic acids/bases or amino acids.

10 The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The degree of identity shared between sequences is typically expressed in term of percentage identity
15 between the two sequences and is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions (i.e. overlapping positions) x 100). Preferably, the two sequences being compared are of the same or substantially the same length.

The skilled person will be aware of the fact that several different computer
20 programs are available to determine the homology between two sequences. For instance, a comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percentage identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)) algorithm which
25 has been incorporated into the GAP program in the Accelrys GCG software package (available at <http://www.accelrys.com/products/gcg/>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is
30 not significantly altered when using different algorithms.

In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the Accelrys GCG software package (available at <http://www.accelrys.com/products/gcg/>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In

another embodiment, the percent identity two amino acid or nucleotide sequence is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989) which has been incorporated into the ALIGN program (version 2.0) (available at the ALIGN Query using sequence data of the Genestream server IGH Montpellier France
5 <http://vega.igh.cnrs.fr/bin/align-guess.cgi>) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the BLASTn and BLASTx programs (version 2.0) of Altschul, *et al.*
10 (1990) J. Mol. Biol. 215:403—10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to oxidoreductase nucleic acid molecules of the invention. BLAST protein searches can be performed with the BLASTx program, score = 50, wordlength = 3 to
15 obtain amino acid sequences homologous to oxidoreductase protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTx and BLASTn) can be used. See the homepage of
20 the National Center for Biotechnology Information at <http://www.ncbi.nlm.nih.gov/>.

As used herein, the term "selectively hybridizing", "hybridizes selectively" and similar terms are intended to describe conditions for hybridization and washing under which nucleotide sequences at least 66%, at least 70%, at least 75%, at least 80%, more preferably at least 85%, even more preferably at least 90%, preferably at least
25 95%, more preferably at least 98% or more preferably at least 99% homologous to each other typically remain hybridized to each other. That is to say, such hybridizing sequences may share at least 45%, at least 50%, at least 55%, at least 60%, at least 65, at least 70%, at least 75%, at least 80%, more preferably at least 85%, even more preferably at least 90%, more preferably at least 95%, more preferably at least 98% or
30 more preferably at least 99% sequence identity.

A preferred, non-limiting example of such hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 1 X SSC, 0.1% SDS at about 50°C, preferably at about 55°C, preferably at about 60°C and even more preferably at about 65°C.

Highly stringent conditions include, for example, hybridization at about 68°C in 5x SSC/5x Denhardt's solution / 1.0% SDS and washing in 0.2x SSC/0.1% SDS at room temperature. Alternatively, washing may be performed at 42°C.

The skilled artisan will know which conditions to apply for stringent and highly
5 stringent hybridization conditions. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, N.Y.).

Of course, a polynucleotide which hybridizes only to a poly A sequence (such
10 as the 3' terminal poly(A) tract of mRNAs), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to specifically hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

15 In a typical approach, gene libraries constructed from other organisms, e.g. a bacterium, in particular from the micro-organism family Trichomaceae, for example from the genus *Burkholderia* can be screened such as *Burkholderia phytofirmans*.

For example, *Burkholderia* strains can be screened for homologous
oxidoreductase polynucleotides by Southern blot analysis. Upon detection of
20 homologous DNA restriction fragments according to the invention, gene libraries can be constructed from chromosomal fragments of the same size from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, if the microorganism is a eukaryote, the mRNA transcript of the oxidoreductase HmfH can be identified by Northern hybridization and upon identification of the transcript, cDNA
25 libraries can be prepared using total RNA isolated from the eukaryotic microorganism.

Homologous gene sequences can be isolated, for example, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences as taught herein.

The template for the reaction can be total chromosomal DNA from the strain
30 known or suspected to express a polynucleotide according to the invention. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a new oxidoreductase nucleic acid sequence, or a functional equivalent thereof.

Alternatively the template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspected to express a polynucleotide according to the invention. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a new
5 oxidoreductase nucleic acid sequence, or a functional equivalent thereof.

The PCR fragment can then be used to isolate a full-length cDNA clone by a variety of known methods. For example, the amplified fragment can be labelled and used to screen a bacteriophage or cosmid cDNA library. Alternatively, the labelled fragment can be used to screen a genomic library.

10 PCR technology also can be used to isolate full-length cDNA sequences from other organisms. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.

15 The resulting RNA/DNA hybrid can then be "tailed" (e.g., with guanines) using a standard terminal transferase reaction, the hybrid can be digested with RNase H, and second strand synthesis can then be primed (e.g., with a poly-C primer). Thus, cDNA sequences upstream of the amplified fragment can easily be isolated. For a review of useful cloning strategies, see e.g., Sambrook *et al.*, supra; and Ausubel *et al.*, supra.

20 Another aspect of the invention pertains to vectors, including cloning and expression vectors, comprising a polynucleotide of the invention encoding a oxidoreductase protein or a functional equivalent thereof and methods of growing, transforming or transfecting such vectors in a suitable host cell, for example under conditions in which expression of a polypeptide of the invention occurs. As used herein,
25 the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.

Polynucleotides of the invention can be incorporated into a recombinant replicable vector, for example a cloning or expression vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the
30 invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells are described below.

The vector into which the expression cassette or polynucleotide of the invention is inserted may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of the vector will often depend on the host cell into which it is to be introduced.

5 A vector according to the invention may be an autonomously replicating vector, i. e. a vector which exists as an extra-chromosomal entity, the replication of which is independent of chromosomal replication, e. g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome (s) into which it has been integrated.

10 One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal
15 mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in
20 recombinant DNA techniques are often in the form of plasmids. The terms "plasmid" and "vector" can be used interchangeably herein as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as cosmid, viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses) and phage vectors which serve equivalent
25 functions.

Vectors according to the invention may be used *in vitro*, for example for the production of RNA or used to transfect or transform a host cell.

A vector of the invention may comprise two or more, for example three, four or five, polynucleotides of the invention, for example for overexpression.

30 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed.

Within a vector, such as an expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell), i.e. the term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence such as a promoter, enhancer or other expression regulation signal "operably linked" to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences or the sequences are arranged so that they function in concert for their intended purpose, for example transcription initiates at a promoter and proceeds through the DNA sequence encoding the polypeptide.

The term "regulatory sequence" or "control sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signal). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990).

The term regulatory or control sequences includes those sequences which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in a certain host cell (e.g. tissue-specific regulatory sequences).

A vector or expression construct for a given host cell may thus comprise the following elements operably linked to each other in a consecutive order from the 5'-end to 3'-end relative to the coding strand of the sequence encoding the polypeptide of the first invention: (1) a promoter sequence capable of directing transcription of the nucleotide sequence encoding the polypeptide in the given host cell ; (2) optionally, a signal sequence capable of directing secretion of the polypeptide from the given host cell into a culture medium; (3) a DNA sequence of the invention encoding a mature and preferably active form of a polypeptide having cellobiohydrolase activity; and preferably also (4) a transcription termination region (terminator) capable of terminating transcription downstream of the nucleotide sequence encoding the polypeptide.

Downstream of the nucleotide sequence according to the invention there may be a 3' untranslated region containing one or more transcription termination sites (e. g. a terminator). The origin of the terminator is less critical. The terminator can, for example,

be native to the DNA sequence encoding the polypeptide. However, preferably a yeast terminator is used in yeast host cells and a filamentous fungal terminator is used in filamentous fungal host cells. More preferably, the terminator is endogenous to the host cell (in which the nucleotide sequence encoding the polypeptide is to be expressed). In the transcribed region, a ribosome binding site for translation may be present. The coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.

Enhanced expression of the polynucleotide of the invention may also be achieved by the selection of heterologous regulatory regions, e. g. promoter, secretion leader and/or terminator regions, which may serve to increase expression and, if desired, secretion levels of the protein of interest from the expression host and/or to provide for the inducible control of the expression of a polypeptide of the invention.

It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The vectors, such as expression vectors, of the invention can be introduced into host cells to thereby produce proteins or peptides, encoded by nucleic acids as described herein (e.g. oxidoreductase proteins, mutant forms of oxidoreductase proteins, fragments, variants or functional equivalents thereof, fusion proteins, etc.).

The vectors, such as recombinant expression vectors, of the invention can be designed for expression of oxidoreductase proteins in prokaryotic or eukaryotic cells. For example oxidoreductase proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors), filamentous fungi, yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Representative examples of appropriate hosts are described hereafter.

Appropriate culture media and conditions for the above-described host cells are known in the art.

As set out above, the term "control sequences" or "regulatory sequences" is defined herein to include at least any component which may be necessary and/or advantageous for the expression of a polypeptide. Any control sequence may be native or foreign to the nucleic acid sequence of the invention encoding a polypeptide. Such control sequences may include, but are not limited to, a promoter, a leader, optimal

translation initiation sequences (as described in Kozak, 1991, J. Biol. Chem. 266:19867-19870), a secretion signal sequence, a pro-peptide sequence, a polyadenylation sequence, a transcription terminator. At a minimum, the control sequences typically include a promoter, and transcriptional and translational stop signals.

5 A stably transformed microorganism is one that has had one or more DNA fragments introduced such that the introduced molecules are maintained, replicated and segregated in a growing culture. Stable transformation may be due to multiple or single chromosomal integration (s) or by (an) extrachromosomal element(s) such as (a) plasmid vector(s). A plasmid vector is capable of directing the expression of
10 polypeptides encoded by particular DNA fragments.

Expression may be constitutive or regulated by inducible(or repressible) promoters that enable high levels of transcription of functionally associated DNA fragments encoding specific polypeptides.

15 Isolation of the oxidoreductase

The oxidoreductase or DNA material expressing the oxidoreductase may be isolated from an organism, preferably a microorganism that expresses the oxidoreductase. Preferably, the microorganism is capable of using HMF, but this is not necessary. The microorganism preferably is chosen from the group consisting of:
20 *Cupriavidus*, *Burkholderia*, *Bradyrhizobium*, *Methylobacterium*; *Cupriavidus basilensis*, *Burkholderia phytofirmans*, *Bradyrhizobium japonicum*, *Methylobacterium radiotolerans*, *Cupriavidus basilensis* HMF14, *Burkholderia phytofirmans* PsJN, *Bradyrhizobium japonicum* USDA110, *Methylobacterium radiotolerans* JCM2831.

Most preferred oxidoreductase useful in the present invention is using a HMF
25 and is an oxidoreductase isolated from *Cupriavidus basilensis* HMF 14 herein, deposited in accordance with the Budapest Treaty on International Recognition of the Deposits of Microorganisms for the Purpose of Patent Procedures at the DSMZ: *Cupriavidus basilensis* HMF14 = DSM 22875, deposition date: August 19, 2009, depositor TNO, Schoemakerstraat 97, 2628VK Delft, Netherlands.

30 We have thus isolated the HMF-utilizing bacterium, *Cupriavidus basilensis* strain HMF14, and identified the genes involved in the HMF degradative pathway. One of the genes (herein defined as *hmfH*) encoded a 579-amino acid, 62 kDa FAD-dependent oxidoreductase that was found to oxidize furfuryl alcohol, furfural, HMF, and 5-hydroxymethyl-furoic acid. The alcohol / aldehyde groups at C2 and C5, in these

molecules were oxidized, without the requirement of additional nucleic acid construct encoding a reductase, though the presence of such activities may be advantageous. (see Figure 1).

The present invention thus provides polynucleotides encoding polypeptides, e.g. enzymes having oxidoreductase (EC 1.1 + EC 1.2 activities) activity. Enzymes are
5 herein a subclass of polypeptides.

Oxidation reaction

The oxidation reaction is herein one or more reaction of an oxidant with a furanic
10 compound in the presence of the oxidoreductase of the invention and one or more co-enzymes (described herein below). The oxidation reaction may comprise one oxidation reaction step resulting in a product (e.g. the oxidation of HMF-acid to FDCA). Alternatively it may comprise more than one oxidation reaction step, each step resulting in an intermediate, where the last intermediate is the final product (e.g. the oxidation of
15 HMF to FDCA). Examples of oxidation reactions are given in Fig. 1.

One oxidation reaction is the production of 2,5-furandicarboxylic acid (FDCA), wherein one or more furanic precursor of FDCA is converted to FDCA, by reaction with an oxidant in the presence of an oxidoreductase catalyst and one or more coenzyme, wherein the oxidoreductase catalyst comprises a polypeptide according to the invention.
20 The furanic precursor of FDCA may be chosen from the group consisting of 5-hydroxymethylfurfural (HMF), 2,5-dihydroxymethyl furan (HMF alcohol) and 5-hydroxymethyl-2-furancarboxylic acid (HMF acid), preferably the furanic precursor is HMF. HMF may be obtained from one or more hexose sugars by heating in presence of acid, in a conventional way. The hexose sugars may be obtained from biomass. The
25 oxidation reaction may also be a process for the production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid) wherein one or more furanic precursor of HMF acid is converted to HMF acid by reaction with an oxidant in the presence of an oxidoreductase catalyst and one or more coenzyme, wherein the oxidoreductase catalyst comprises a polypeptide to the invention. In one embodiment, the furanic precursor of HMF acid is
30 chosen from the group chosen from 5-hydroxymethylfurfural (HMF) and 2,5-dihydroxymethyl furan (HMF alcohol). Other oxidation processes are possible.

The oxidation reactions are preferably conducted at relatively mild temperature, i.e. 10-80°C, more preferably 20-45°C, most preferably around from 25-40°C. The pH during the reaction is preferably pH 3 to 8, more preferably around pH 7. The reaction

time is 6 – 18 hrs using atmospheric oxygen or pure oxygen and preferably the enzyme is reactive for longer times.

The reactor may be any suitable (aerated) bioreactor. It may be operated in batch, continuous or preferably in fed-batch.

5 Oxidation products such as FDCA, HMF-acid, etc. may be recovered from the reaction mixture by cooling/recrystallisation and separation of the crystallized oxidation product e.g. crystallized FDCA. However, other recovery methods are suitable, such as but not limited to acid precipitation and solvent extraction, as known in the art.

10 Optionally, the reaction takes place in the presence of a coenzyme. The coenzyme may be nicotinamide adenine dinucleotide (NAD⁺) and/or flavin adenine dinucleotide (FAD) and/or pyrroloquinoline quinolone (PQQ). A synergistic effect was found in the oxidation reaction of the invention with dehydrogenase activity, e.g. endogenous dehydrogenation activity found a cell in which the oxidation reaction takes place or present in a cell extract of such a cell. Process for the production of a polymer
15 from one or more monomer, wherein one of the monomer is FDCA according

Oxidant

The oxidant during the reactions according to the invention may be any oxidant, preferably oxygen. The most economical source of oxygen is air. This is advantageous in that air is easily obtained from the atmosphere at no cost, no toxicity and no need to
20 remove it after the reaction. Alternatively, one may employ a molecular oxygen liberating system. The oxygen-generating system may in principle be chosen from the various oxygen-generating systems which have been disclosed in the art. For example, one may use the catalase enzymes already present in the reaction mixture to generate oxygen from hydrogen peroxide.

25

Furanic compounds

Furanic compounds are herein understood to be any compound having a furan group that may be oxidized to 2,5-furan-dicarboxylic acid or a precursor thereof. Preferred furan compounds include hydroxymethylfurfural (HMF), hydroxymethylfuran
30 carboxylic acid (HMF acid), 2,5-dihydroxymethylfuran (HMF alcohol), The furan ring or any or its substitutable sidegroup may be substituted, e.g. with OH, C1-C10 alkyl, alkyl, allyl, aryl or RO- ether moiety, including cyclic groups, in the furan ring on any available position.

Expression of oxidoreductase

Regardless of the exact mechanism utilized for expression of enzymes, it is contemplated that such expression is transferable by the introduction of genes encoding these enzymes into another host cell by methods known in the art. Genetic elements as
5 herein defined include nucleic acids (generally DNA or RNA) having expressible coding sequences for products such as proteins, specifically enzymes, apoproteins or antisense RNA, which express or regulate expression of relevant enzymes. The expressed proteins can function as enzymes, repress or derepress enzyme activity or control expression of enzymes. Recombinant DNA encoding these expressible sequences can
10 be either chromosomal (integrated into the host cell chromosome by, for example, homologous recombination) or extra-chromosomal (for example, carried by one or more plasmids, cosmids and other vectors capable of self replication). It is understood that the recombinant DNA utilized for transforming the host cell in accordance with this invention can include, in addition to structural genes and transcription factors, expression control
15 sequences, including promoters, repressors and enhancers, that act to control expression or derepression of coding sequences for proteins, apoproteins or antisense RNA. For example, such control sequences can be inserted into wild-type host cells to promote overexpression of selected enzymes already encoded in the host cell genome, or alternatively they can be used to control synthesis of extrachromosomally encoded
20 enzymes.

Recombinant DNA can be introduced into the host cell by any means, including, but not limited to, plasmids, cosmids, phages, yeast artificial chromosomes or other vectors that mediate transfer of genetic elements into a host cell. These vectors can include an origin of replication, along with cis-acting control elements that control
25 replication of the vector and the genetic elements carried by the vector. Selectable markers can be present on the vector to aid in the identification of host cells into which genetic elements have been introduced.

Means for introducing genetic elements into a host cell (e.g. cloning) are well known to the skilled artisan. One can utilize an extrachromosomal multi-copy plasmid
30 vector to insert the genetic elements in accordance with the present invention. Plasmid-borne introduction of the genetic element into host cells involves an initial cleaving of a plasmid vector with a restriction enzyme, followed by ligation of the plasmid and genetic elements encoding for the targeted enzyme species in accordance with the invention. Upon recircularization of the ligated recombinant plasmid, infection (e.g., packaging in

phage lambda) or other mechanism for plasmid transfer (e.g., electroporation, microinjection, etc.) is utilized to transfer the plasmid into the host cell. Plasmids suitable for insertion of genetic elements into the host cell are well known to the skilled artisan.

Other gene cloning methods include, but are not limited to, direct integration of the genetic material into the chromosome. This can occur by a variety of means, including cloning the genetic elements described herein on non-replicating plasmids flanked by homologous DNA sequences of the host chromosome; upon transforming said recombinant plasmid into a host the genetic elements can be introduced into the chromosome by DNA recombination. Such recombinant strains can be recovered if the integrating DNA fragments contain a selectable marker, such as antibiotic resistance. Alternatively, the genetic elements can be directly introduced into the chromosome of a host cell without use of a non-replicating plasmid. This can be done by synthetically producing DNA fragments of the genetic elements in accordance to the present invention that also contain homologous DNA sequences of the host chromosome. Again if these synthetic DNA fragments also contain a selectable marker, the genetic elements can be inserted into the host chromosome.

Host cell

Another embodiment of the invention is a cell comprising a polypeptide, a polynucleotide, a nucleic acid construct or a vector according to the invention. A host cell is a cell in which the a polypeptide, a polynucleotide, a nucleic acid construct or a vector can suitably be expressed.

The oxidoreductase may be favourably expressed in a host cell. The host cell according to the invention may be any host cell. The cell may be a prokaryote cell, a eukaryote cell, a plant cell or an animal cell. In such cell one or more genes may be deleted, knocked-out or disrupted in full or in part, wherein optionally one or more genes encode for protease. According to an embodiment, the host cell according to the invention is a eukaryotic host cell. Preferably, the eukaryotic cell is a mammalian, insect, plant, fungal, or algal cell. Preferred mammalian cells include e.g. Chinese hamster ovary (CHO) cells, COS cells, 293 cells, PerC6 cells, and hybridomas. Preferred insect cells include e.g. Sf9 and Sf21 cells and derivatives thereof. More preferably, the eukaryotic cell is a fungal cell, i.e. a yeast cell, such as *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* strain. More preferably from *Kluyveromyces lactis*, *S. cerevisiae*, *Hansenula polymorpha*,

Yarrowia lipolytica and *Pichia pastoris*, or a filamentous fungal cell. Most preferably, the eukaryotic cell is a filamentous fungal cell.

"Filamentous fungi" include all filamentous forms of the subdivision *Eumycota* and *Oomycota* (as defined by Hawksworth *et al.*, In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. Filamentous fungal strains include, but are not limited to, strains of *Acremonium*, *Agaricus*, *Aspergillus*, *Aureobasidium*, *Chrysosporium*, *Coprinus*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Panerochaete*, *Pleurotus*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, and *Trichoderma*.

Preferred filamentous fungal cells belong to a species of an *Aspergillus*, *Chrysosporium*, *Penicillium*, *Talaromyces* or *Trichoderma* genus, and most preferably a species of *Aspergillus niger*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus sojae*, *Aspergillus fumigatus*, *Talaromyces emersonii*, *Aspergillus oryzae*, *Chrysosporium lucknowense*, *Trichoderma reesei* or *Penicillium chrysogenum*. When the host cell according to the invention is an *Aspergillus* host cell, the host cell preferably is CBS 513.88, CBS124.903 or a derivative thereof.

According to another embodiment, the host cell according to the invention is a prokaryotic cell. Preferably, the prokaryotic host cell is bacterial cell. The term "bacterial cell" includes both Gram-negative and Gram-positive microorganisms. Suitable bacteria may be selected from e.g. *Escherichia*, *Anabaena*, *Caulobacter*, *Gluconobacter*, *Rhodobacter*, *Pseudomonas*, *Paracoccus*, *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Rhizobium* (*Sinorhizobium*), *Flavobacterium*, *Klebsiella*, *Enterobacter*, *Lactobacillus*, *Lactococcus*, *Methylobacterium*, *Staphylococcus* or *Streptomyces*. Preferably, the bacterial cell is selected from the group consisting of *B. subtilis*, *B. amyloliquefaciens*, *B. licheniformis*, *B. pumilis*, *B. megaterium*, *B. halodurans*, *B. pumilus*, *Gluconobacter oxydans*, *Caulobacter crescentus* CB 15, *Methylobacterium extorquens*, *Rhodobacter sphaeroides*, *Pseudomonas zeaxanthinifaciens*, *Pseudomonas putida*, *Pseudomonas putida* S12, *Paracoccus denitrificans*, *E. coli*, *C. glutamicum*, *Staphylococcus carnosus*, *Streptomyces lividans*, *Sinorhizobium meliloti* and *Rhizobium radiobacter*.

Several strains of filamentous fungi are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent
5 Culture Collection, Northern Regional Research Center (NRRL): e.g. the strains *Aspergillus niger* CBS 513.88, *Aspergillus oryzae* ATCC 20423, IFO 4177, ATCC 1011, ATCC 9576, ATCC14488-14491, ATCC 11601, ATCC12892, *P. chrysogenum* CBS 455.95, *Penicillium citrinum* ATCC 38065, *Penicillium chrysogenum* P2, *Talaromyces emersonii* CBS 124.902, *Acremonium chrysogenum* ATCC 36225 or ATCC 48272,
10 *Trichoderma reesei* ATCC 26921 or ATCC 56765 or ATCC 26921, *Aspergillus sojae* ATCC11906, *Chrysosporium lucknowense* ATCC44006. Also derivatives thereof may be used.

According to another embodiment, the host cell according to the invention is a prokaryotic cell. Preferably, the prokaryotic host cell is bacterial cell. The term "bacterial
15 cell" includes both Gram-negative and Gram-positive microorganisms. Suitable bacteria may be selected from e.g. *Escherichia*, *Anabaena*, *Caulobacter*, *Gluconobacter*, *Rhodobacter*, *Pseudomonas*, *Paracoccus*, *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Rhizobium* (*Sinorhizobium*), *Flavobacterium*, *Klebsiella*, *Enterobacter*, *Lactobacillus*, *Lactococcus*, *Methylobacterium*, *Staphylococcus* or *Streptomyces*. Preferably, the
20 bacterial cell is selected from the group consisting of *B. subtilis*, *B. amyloliquefaciens*, *B. licheniformis*, *B. pumilis*, *B. megaterium*, *B. halodurans*, *B. pumilus*, *G. oxydans*, *Caulobacter crescentus* CB 15, *Methylobacterium extorquens*, *Rhodobacter sphaeroides*, *Pseudomonas putida*, *Paracoccus zeaxanthinifaciens*, *Paracoccus denitrificans*, *E. coli*, *C. glutamicum*, *Staphylococcus carnosus*, *Streptomyces lividans*,
25 *Sinorhizobium meliloti* and *Rhizobium radiobacter*.

For specific uses of a compound produced in a host cell according to the invention, the selection of the host cell may be made according to such use. Where e.g. the compound produced in a host cell according to the invention is to be used in food applications, a host cell may be selected from a food-grade organism such as
30 *Saccharomyces cerevisiae*. Specific uses include, but are not limited to, food, (animal) feed, pharmaceutical, agricultural such as crop-protection, and/or personal care applications.

The invention further relates to method for the preparation of a polypeptide having oxidoreductase activity, which method comprises cultivating a cell according to

the invention under conditions which allow for expression of said polypeptide and, optionally, recovering the expressed polypeptide and to a polypeptide obtainable by a that method.

5 **Feedstock**

Agricultural crops naturally rich in fructans (e.g., topinambur or chicory roots) may be converted to an HMF-rich feedstock by conventional (combined) hydrolysis and thermochemical processing. The technology to generate HMF from fructose is well-established and robust. Also glucose-rich feedstock can be utilized, but the thermochemical formation of HMF proceeds more efficiently from fructose. Therefore, an additional enzymatic step can be included to convert glucose to fructose, using glucose isomerase. The latter process is well-established in food industry for producing high-fructose corn syrup (HFCS) from hydrolysed starch. To avoid competition with food applications, lignocellulosic hydrolysate would be the preferred feedstock for producing HMF/FDCA.

Biotransformation

For biotransformation of HMF to FDCA, a robust whole-cell biocatalyst is employed (free or immobilized cells) that expresses the *Cupriavidus basilensis* HMF oxidoreductase described herein before. A whole-cell biocatalyst has several advantages over an enzyme catalyst in this process: the HMF oxidoreductase is protected from chemical inactivation by the -highly reactive substrate and host-indigenous dehydrogenases can assist HMF oxidoreductase in the first two oxidation steps leading from HMF to (probably) the corresponding monoacid, which then is converted to the diacid by HmfH. Preferably, additional measures may be required to secure cofactor regeneration. The whole-cell biocatalyst should allow minimal processing of the HMF feed stream, i.e., preferably tolerate low pH, high T and the toxic compounds (among which the substrate) generated in the hydrolysis/thermochemical conversion of the feedstock. *Pseudomonas putida* S12 may qualify as a suitable host organism in view of its tolerance to diverse chemical stressors, its relatively wide pH range and the presence of indigenous dehydrogenases that assist HMF oxidoreductase resulting in a more efficient biotransformation of HMF to FDCA.

Alternative to the whole cell biocatalyst, in a similar way as the whole-cell biocatalyst, a cell lysate, purified enzyme, or an immobilized enzyme alone or as enzyme mixture may be used.

5 **Product and biomass recovery**

After biotransformation, the cells may be separated from the broth by established methods and re-used. FDCA may be recovered from the cell-free broth by acid precipitation and redissolved in a suitable organic solvent at elevated temperature. After dissolution, FDCA may be recovered by acid precipitation and solvent extraction, or
10 other purification methods known in the art, at high purity in the di-acid form, in case this is desired.

Uses of FDCA

FDCA may be used as an alternative for terephthalate in the production of
15 polyesters. It may also be used as a substrate for a large variety of valuable compounds. For instance it is a known substrate for the production of succinic acid, 2,5-bis(aminomethyl)-tetrahydrofuran, 2,5-dihydroxymethyl-tetrahydrofuran, 2,5-dihydroxymethylfuran and 2,5-furandicarbaldehyde. FDCA may be used in the production of coatings, e.g. in alkyd resin and thermoplastic coatings. It may also be
20 used as a xylene equivalent in biofuels and as solvent.

FDCA may be esterified, and the esters may be used as plasticizers. It may be converted to its diol, that may be used in PET-like polyesters and polyurethanes. Further it may be converted into its diamine, the diamine may be used as chain extender and the diamine may be converted into di-isocyanate, which can be used in the production of
25 polyurethanes. Through the process according to the invention FDCA, and the products prepared from FDCA, can be made from biomass, including lignocellulosic biomass, through biotransformation.

EXAMPLES

30

General Methodology

Strains and plasmids *Cupriavidus basilensis* HMF 14, deposited at the DSMZ: *Cupriavidus basilensis* HMF14 = DSM 22875, deposition date: August 19, 2009 is a soil

isolate that is able to use furans as a sole carbon source. *Pseudomonas putida* S12 (ATCC 700801) was used as the host for expression of HMF oxidoreductase. *Escherichia coli* DH5 α (Invitrogen) was used for general cloning purposes. The pUCP22-derived *E. coli*-*P. putida* shuttle plasmid pJT'mcs (unpublished) was used for the expression of HMF oxidoreductase under control of the constitutive *tac* promoter. For replication in *E. coli*, the pUC origin of replication is employed; for replication in *P. putida*, the pRO1600 origin of replication is employed. Expression of the *hmfH* gene is driven from the constitutive *tac* promoter. The β -lactamase marker gene (*bla*) is used for antibiotic selection (ampicillin resistance) in *E. coli*. For antibiotic selection in *P. putida*, the gentamicin acetyltransferase marker gene (*gmR*) is used.

A Plasmid map of HmfH expression vector pJT'hmfH is given in Fig. 2. Ptac', *tac* promoter; rep, broad host range origin of replication; gmR, gentamicin resistance gene; bla, beta-lactamase; pUC ori, origin of replication for *E. coli*.

Media & Culture conditions Mineral salts medium (MM) was used as a defined medium. MM contained the following (per liter of demineralized water): 3.88 g of K₂HPO₄, 1.63g of NaH₂PO₄, 2.0 g of (NH₄)₂SO₄, 0.1 g of MgCl₂·6H₂O, 10 mg of EDTA, 2 mg of ZnSO₄·7H₂O, 1 mg of CaCl₂·2H₂O, 5 mg of FeSO₄·7H₂O, 0.2 mg of Na₂MoO₄·2H₂O, 0.2 mg of CuSO₄·5H₂O, 0.4 mg of CoCl₂·6H₂O, and 1 mg of MnCl₂·2H₂O, supplemented with a carbon source as specified. Luria broth (L-broth: 10 g/l Bacto trypton (Difco), 5 g/l yeast extract (Difco), 5 g/l NaCl) was used as a complete medium for propagation of *P. putida* S12 and derivative strains, *C. basilensis* HMF14 and *E. coli* DH5 α and derivatives. Solid L-broth was solidified with 2 % (w/v) of agar (Difco).

For fed batch experiments, the initial batch phase was performed in 1 l of adapted mineral salts medium with the following composition: 3.88 g of K₂HPO₄, 1.63g of NaH₂PO₄, 2.0 g of (NH₄)₂SO₄, 0.2 g of MgCl₂·6H₂O, 20 mg of EDTA, 4 mg of ZnSO₄·7H₂O, 2 mg of CaCl₂·2H₂O, 10 mg of FeSO₄·7H₂O, 0.4 mg of Na₂MoO₄·2H₂O, 0.4 mg of CuSO₄·5H₂O, 0.8 mg of CoCl₂·6H₂O, 2 mg of MnCl₂·2H₂O, 10 mg/L gentamicin and 100 mM glycerol. After depletion of the initial glycerol, the feed was started and controlled to allow maximum growth while maintaining glycerol as the limiting substrate in the culture. The feed solution contained (per l): 368.4 g glycerol and 10 g/L MgCl₂·6H₂O, and 12.6 g/L HMF.

Antibiotics: ampicillin (amp) was added to 100 µg/ml for *E. coli*. Gentamicin (gm) was added to 30 µg/ml in Luria broth and 10 µg/ml in mineral salts medium for *P. putida* S12. Antibiotics were purchased from Sigma-Aldrich.

5 Culturing: *P. putida* and *C. basilensis* were cultured at 30 °C. *E. coli* was cultured at 37 °C. Shake flask experiments on MM were performed in Boston bottles (Alltech applied sciences BV; Breda, The Netherlands) in a horizontally shaking incubator. Shake flask experiments on L-broth were performed in Erlenmeyer flasks with cotton plugs in a horizontally shaking incubator. Fed-batch experiments were performed in 1 l fermentors
10 (New Brunswick Scientific) using a BioFlo110 controller. Initial batch fermentation was started with washed cells from an overnight preculture in 100 ml MM supplemented with 40mM glycerol and 2mM glucose. The initial stirring speed was set to 200 rpm and air was supplied to the head space at 1 l min⁻¹ using a M+W Instruments D-5111 mass-flow controller. Dissolved oxygen tension (DO) was continuously monitored with an InPro
15 model 6900 probe (Mettler Toledo BV; Tiel, The Netherlands) and maintained at 30 % air saturation by automatic adjustment of the stirring speed to a maximum of 1000 rpm. When the maximum stirring speed was reached, air was replaced with purified oxygen at a flow of 0.2 l min⁻¹ and the maximum stirring speed was set to 800 rpm. The pH was maintained at 7.0 by automatic addition of 25 % NH₄OH during initial batch phase,
20 during the feed phase the pH was kept constant by automatic addition of 10 mM NaOH. The temperature was kept at 30°C.

Assays & Analytical methods: Cell dry weight (CDW) content of bacterial cultures was determined by measuring optical density at 600 nm (OD₆₀₀) using a
25 Biowave Cell Density Meter (WPA Ltd) or a µQuant MQX200 universal microplate spectrophotometer (Biotek), using flat-bottom 96-well microplates (Greiner). An OD₆₀₀ of 1.0 corresponds to 0.56 g CDW / L (Biowave) or 1.4 g CDW / L (µQuant) for *P. putida*.

HPLC analyses: FDCA, HMF, HMF-alcohol and HMF-acid were analyzed by RP-
30 HPLC (Agilent 1100 system) using a diode array detector set at 230 nm. The column used was a Zorbax Eclipse XDB-C8 (pore size of 80Å, surface area of 180 m²/g, Agilent) operated at 25 °C. As eluent, a gradient of acetonitrile in 20 mM KH₂PO₄ (pH 2 or pH 6) with 1 % acetonitrile was used at a flow of 1.2 ml / min, increasing from 0 to 5 % in 3.5 min and from 5 to 40 % in 2.5 min.

Preparation of cell extracts: Cell extracts of wildtype *C. basilensis* HMF14 or *P. putida* S12 transformants expressing HMF oxidoreductase were prepared from 50-ml late exponential growth phase cultures using MM supplemented with either 12 mM succinate (*C. basilensis* HMF14, OD₆₀₀ ≈ 1.5) or 20 mM glucose (*P. putida* S12, OD₆₀₀ ≈ 4). The cultures were harvested by centrifugation and resuspended in 3 ml of assay buffer. Cells were disrupted by sonication, using either a Branson sonifier (micro tip at pulse mode, output set at 3 and percentage duty cycle set to 40 %; 3 cycles of sonication: 45 s of pulsing and 15 s pause) or a Sonics Vibra-Cell (Sonics&Materials, USA) (5 mm tapered microtip; pulse mode set to 1 min (0,5 s pulse, 2 sec pause). After sonication, debris was removed by centrifuging at 8228 × *g* for 3 min at 4 °C. The supernatant was desalted using a PD10 gel filtration column (GE healthcare) and used as cell extract for HMF oxidoreductase assays. Protein concentration was measured using Bradford reagent (Sigma-Aldrich).

HMF oxidoreductase assay: HMF oxidoreductase assays were performed in cell extracts of wildtype *C. basilensis* HMF14 or *P. putida* S12 transformants expressing the *C. basilensis* HMF14 HMF oxidoreductase. As a negative control, wildtype *P. putida* S12 or a *C. basilensis* HMF14 mutant was used that carried a transposon insertion in the *hmfH* gene. Cell extract was incubated with furfural, furfuryl alcohol, HMF or HMF-acid at 30 °C under oxygenated conditions. The reaction mixture contained 1ml cell extract, 976 µl oxygen-saturated MM, 20 µl of a 2 mM flavin adenine dinucleotide (FAD) solution and 4 µl of a 0.5 M stock of substrate (furfural, furfuryl alcohol, HMF, or HMF acid. Samples were drawn at set intervals and the reaction was immediately stopped by addition of HCl to a final concentration of 1 M. Substrate and product concentrations in the samples were determined by HPLC. As an oxygen-depleted control, the different components of the reaction mixture were depleted of oxygen by a continuous stream of nitrogen gas and the same reaction mixture was incubated in headspace vials with a rubber stopper under nitrogen gas.

Chemicals: Analytical standard of FDCA was purchased from Immunosource B.V. (Halle-Zoersel, Belgium). 5-Hydroxymethyl-furoic acid (HMF acid) was purchased from Matrix Scientific (Columbia SC, United States). This compound was found to be highly esterified. Immediately prior to use, a 10 mM solution of the esterified HMF acid

was boiled for two hours in 2 M H₂SO₄, cooled, and adjusted to pH 7.0 with NaOH after addition of 50 mM of phosphate buffer. All other chemicals were purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands).

5 ***Molecular and genetic techniques:*** Genomic DNA was isolated using the DNeasy tissue kit (QIAGEN). Plasmid DNA was isolated with the QIAprep spin miniprep kit (QIAGEN). Agarose-trapped DNA fragments were isolated with the QIAEXII gel extraction kit (QIAGEN).

10 PCR reactions were performed with Accuprime *Pfx* polymerase (Invitrogen) according to the manufacturer's instructions. Primers used to amplify HMF oxidoreductase from genomic DNA of *C. basilensis* HMF14 were FN23: 5'-CGGAATTCCACATGACAAGGGGAGACCG-3' (SEQ ID NO: 1) and FN24: 5'-CGGAATTCGCTTCGGTCTTCAACTCGGATG-3' (SEQ ID NO: 2). Underlined
15 sequences indicate an EcoRI restriction site.

Plasmid DNA was introduced into electrocompetent cells using a Gene Pulser electroporation device (BioRad).

20 Chromosomal DNA flanking the transposon was identified by standard methods known in the art {Ausubel, F.M. et al. Current protocols in molecular biology (Green publishing association, New York; 1987)} and the sequence of the complete genetic loci were obtained by primer walking. Oligonucleotide synthesis and DNA sequencing were performed by MWG Biotech AG (Germany).

25 Other standard molecular biology techniques were performed according to Sambrook and Russell {Sambrook, J, Russel, D.W. Molecular cloning; a laboratory manual (Cold spring Harbor Laboratory Press, New York: 2001)}

30 Example I

FDCA production in cell extract of *C. basilensis* HMF14

When cell extract of *C. basilensis*, from a late log phase preculture (OD₆₀₀ ≈ 1.5) grown on MM supplemented with 12 mM succinate and 3 mM HMF, was incubated with either HMF, or HMF acid, formation of FDCA was observed.

When HMF was used as the substrate, a fast transient accumulation of HMF-acid an HMF-alcohol was observed concurrent with FDCA formation. In desalted cell extract the HMF-acid concentration decreased at a slower rate and FDCA production was slower compared to crude cell extract. Since FDCA was produced in desalted cell extract as well as in crude cell extract, the conversion of HMF to FDCA appeared not to involve cofactors. Nevertheless, cofactors or other low-molecular weight components from crude cell extract appeared to have a synergistic effect on FDCA formation. When HMF-acid was added as the substrate, immediate formation of FDCA was observed in both crude and desalted cell extract. It was furthermore demonstrated that the presence of oxygen was required for FDCA formation as no FDCA was produced under anaerobic conditions. Stoichiometric conversion of HMF acid to FDCA was observed.

Example II

Isolation and characterization of the *hmfH* gene encoding HMF oxidoreductase

The *hmfH* gene was found to encode a 62 317 Da protein belonging to the FAD-dependent glucose-methanol-choline (GMC) oxidoreductase family. This enzyme was shown to have the ability to oxidize HMF-acid to furan-dicarboxylic acid (FDCA). In addition, the enzyme also accepted HMF as the substrate, which was oxidized, via HMF-acid, to FDCA. The highest homology with HmfH in the non-redundant NCBI database was found with the GMC oxidoreductase of *Burkholderia phytofirmans* PsJN (locus tag Bphyt_2180; 68 % identity over a 562-amino acid stretch). Based on the sequence data of the HMF/furfural operon of *C. basilensis* HMF14 other potential HMF/furfural degraders were identified. Selected strains were tested for growth on mineral salts medium with either HMF or furfural as the sole carbon source. The strains that were able to grow on HMF had an *hmfH* orthologue encoding oxidoreductases that are between 45 and 68 % identical to HmfH. One strain (*Burkholderia xenovorans* LB400) was unable to utilize HMF although its oxidoreductase was 44 % identical to HmfH.

Fig. 3 gives a schematic representation of the genetic organization of the furfural and HMF metabolic genes in *C. basilensis* HMF14 (A) and other species (B) that were identified as potential furfural and / or HMF utilizers. Colours correspond to enzyme activities in figure 1. Bold numbers (**x/y**) below arrows indicate the percentage identity (**x**) to the corresponding *C. basilensis* HMF14 protein in a **y** amino-acid stretch. Orthologous genes were identified by BLASTx homology searches in the non-redundant

protein database of the National Center for Biotechnology Information. Hits for the furfural cluster were defined as relevant when orthologues for *hmfA*, *B*, *C*, *D* and *E* were present in a single genome, with the *hmfA* orthologue encoding an enzyme that was at least 50 % identical to HmfA. The same criterion was used to define *hmfF* and *hmfG* orthologues, whereas 40 % identity to HmfH was used as the criterion for *hmfH* orthologues. Numbers in italics indicate genome locus tags of the indicated strain. White arrows depict genes with no metabolic function. C: Overview of growth phenotype of tested strains on mineral salts medium with either furfural or HMF (3 mM) as the sole carbon source. ND: not determined.

In the figures there are given the Nucleotide sequence of the open reading frame encoding HMF-oxidoreductase HmfH (Fig. 4) and the deduced amino acid sequence (Fig. 3).

Example III

Cloning of *hmfH* in *P. putida* S12 and expression of the encoded oxidoreductase

The *hmfH* gene encoding HMF oxidoreductase was cloned into expression vector pJT'mcs. The PCR fragment obtained with primers FN23 and FN24 on *C. basilensis* HMF14 genomic DNA was digested with EcoRI (Fermentas). The digested fragment was ligated into EcoRI-digested and FastAP (Fermentas)-treated pJT'mcs vector, yielding HmfH expression plasmid pJT'hmfH. The correct orientation of the *hmfH* insert was verified by means of control digestion and by nucleotide sequencing known in the art. Expression of HMF oxidoreductase was demonstrated in cell extract of *P. putida*_pJT'hmfH grown in MM + 20 mM glucose and 10 mg/l gentamicin (OD₆₀₀ ≈ 4) by the formation of FDCA using HMF or HMF acid as the substrate (Table 1).

Table 1. Formation of FDCA from HMF or HMF acid in cell extract of *P. putida*_pJT'hmfH. As control, cell extract of *P. putida* S12 harbouring the empty expression vector pJT'mcs was used.

	Oxygen	
	yes	no
cell extract		
desalted	+	-
not desalted	+	-
control, desalted	-	-
control, not desalted	-	-

These results confirmed that the formation of FDCA only occurs in the presence of oxygen, and is catalyzed by the *hmfH*-encoded oxidoreductase. When HMF was used as the substrate, transient accumulation of HMF-acid was observed both in desalted and crude cell extract. The formation of HMF-acid in desalted cell extract (low-MW cofactors removed) indicated HmfH not only oxidized HMF-acid to FDCA, but can also oxidize HMF to its mono-carboxylic acid form.

In addition to HmfH, also apparently unspecific dehydrogenases that are indigenous to *P. putida* S12 can form HMF acid from HMF (Table 2), provided that the reducing equivalents are not removed by desalting. The aldehyde reductase / alcohol dehydrogenase activity was NADH/NAD⁺ dependent whereas the aldehyde dehydrogenase activity could be supported by a combination of the two artificial electron carriers, PMS and DCPIP, in which PMS is the primary electron carrier and DCPIP is the final electron acceptor. Similar activities were also observed in cell extract of *C. basilensis* HMF14.

Table 2. Non-specific HMF-dehydrogenase activities measured in cell extract of wild type *P. putida* S12.

Enzyme activity	Substrate	Product	Cofactor	<i>P. putida</i> S12
aldehyde reductase	HMF	HMF alcohol	NADH	1106
alcohol dehydrogenase	HMF alcohol	HMF	NAD ⁺	ND
aldehyde dehydrogenase	HMF	HMF acid	PMS/DCPIP	8

ND: not determined for lack of commercially available substrate. Activities depicted in U g⁻¹ protein. PMS/DCPIP: phenazine methosulphate / 2,6-dichlorophenol-indophenol.

Formation of FDCA, HMF-alcohol (H-oh) and HMF-acid (H-acid) from HMF in crude cell extract of *P. putida* S12 pJT'hmfH is shown in Fig. 4. Fig. 4 illustrates the synergistic effects of endogenous dehydrogenases and HmfH in *P. putida* S12 pJT'hmfH

cell extract. First, a rapid decrease in HMF was observed concomitant with the formation of HMF-alcohol which was probably catalysed by aldehyde reductase. At the same time, also HMF-acid (likely via aldehyde dehydrogenase) and FDCA (via HmfH) started to accumulate. Immediately after formation, HMF-alcohol disappeared, probably through
5 re-oxidation to HMF, HMF-acid and FDCA. Only HMF-acid showed significant accumulation prior to being oxidized (almost) completely to FDCA in a 25-h time span. These results suggest that the oxidation of HMF-acid to FDCA was the rate-limiting step in this cell-free system.

Example IV

Whole-cell transformation of HMF to FDCA with *P. putida* S12 expressing HmfH

Because endogenous dehydrogenases of *P. putida* S12 can act synergistically with HmfH in the oxidation of HMF to FDCA by providing an additional means of generating HMF-acid from HMF, a whole-cell biotransformation process of HMF to
15 FDCA may have advantages over an enzymatic process. To investigate this possibility, resting cells, growing cells and disrupted cells were tested for HMF to FDCA production.

Shake flask cultures were grown in 150 ml MM + 40mM glycerol and 2 mM glucose supplemented with 10 mg/L gentamicin in 1-L Erlenmeyer flasks. Cells were harvested at the end of the log phase ($OD_{600} \approx 4$), washed and concentrated in MM
20 supplemented with 19.4 g/L of K_2HPO_4 , 8.15 g/L of NaH_2PO_4 , 40 mM glycerol and 10 mg/L gentamicin. Aliquots (10 ml) of the concentrated cell suspensions (corresponding to 1.65 g of CDW) were incubated with HMF in 250 ml Erlenmeyer flasks and samples were drawn at regular intervals for analysis of FDCA. For resting cells, glycerol was omitted from the resuspension medium and the disrupted cells were obtained by
25 sonication.

As observed previously, HMF was rapidly converted into HMF-alcohol and HMF acid, followed by a decline of HMF acid and concurrent formation of FDCA. Both FDCA production rates and HMF acid decrease rates are presented in Table IV-a, for two concentrations of HMF tested.

30 Table 3. Production of FDCA from HMF and HMF-acid decrease rate using growing cells, resting cells, and sonified cells of *P. putida* S12 pJT'hmfH, at different starting concentrations of HMF.

	HMF-acid decrease rate	FDCA production rate
--	------------------------	----------------------

concentration HMF (mM)	(μmol/ gCDW / h)			(μmol/ gCDW / h)		
	growing cells	resting cells	disrupted cells	growing cells	resting cells	disrupted cells
25	194 ± 10 ^b	120 ^a	73 ^a	145 ± 3.5 ^b	115 ^a	115 ^a
50	377 ± 27 ^b	ND ^c	ND ^c	450 ± 80 ^b	ND ^c	ND ^c

- a) Incomplete conversion of HMF-acid to FDCA was observed.
b) Duplicate experiments; the variation is the maximum deviation from the mean of two independent experiments.
c) ND = not determined

Table 3 shows that FDCA production was more efficient with growing cells of *P. putida* S12 expressing HmfH. The overall FDCA production rate, conversion efficiency, as well as the HMF-acid decrease rate were higher for the growing cell-incubations. In addition, the FDCA production rate was dependent on the initial concentration of HMF suggesting that the system was not saturated.

Example V

Fed-batch FDCA production from HMF with *P. putida* S12 expressing HmfH

Production of FDCA was found to be most efficient with growing cells of *P. putida* S12 expressing HmfH. Therefore, fed-batch experiments were performed to demonstrate the production of FDCA with whole cells of *P. putida* S12 pJT'hmfH.

In the initial phase, *P. putida*_pJT'hmfH was cultured on MM with a feed of glycerol to a cell density of 13 g CDW / l. At the end of this phase, the HMF feed was started, administering HMF at a rate of 0.8 mmol/l/h. Without glycerol-co-feeding, HMF-acid and FDCA were formed at an equal rate of 0.41 mmol / l / h (See Fig. 5). Subsequently the feed was replaced with a solution containing 0.21 M HMF and 4 M glycerol, fed at approximately 5 ml/h. With this glycerol co-feeding, the HMF-acid concentration rapidly declined while the formation of FDCA continued at approximately the same rate (Fig. 5). The experiment was stopped when a total amount of 44,6 mmol

HMF had been added to the fed batch. Results showed almost complete conversion (i.e., 96.5 % efficiency) to FDCA.

In a similar experiment glycerol was co-fed at an average rate of 0.7 mmol / l / h along with HMF. In this fed-batch culture, no accumulation of the HMF acid intermediate was observed and all HMF was converted directly into FDCA (Fig. 6).

Example VI

Purification of FDCA from fermentation broth

The solubility of FDCA at a pH of 1.0 was found to be around 1.5 g/l in water. This property was employed advantageously for recovery of the FDCA product from the fermentation broth. After removal of cells by centrifugation (9500 x g for 5 min), approximately 10 ml 96 % H₂SO₄ was added to 100 ml of the clarified broth at room temperature under continuous stirring until pH 1, in order to precipitate FDCA. The precipitate was recovered by centrifugation at 8228 x g for 10 min and the air-dried pellet was redissolved in methanol at 60 °C. Upon removal of undissolved debris by filtration through a preheated 0.22-μm filter, the filtrate was analyzed for purity by HPLC. The purity of the FDCA recovered from the fermentation broth by the above procedure was approximately 65 %. Further purification of FDCA can be achieved using methods well known in the art.

Example VII

Fed-batch FDCA production from HMF with *P. putida* S12 expressing HmfH

A second fed-batch FDCA production experiment was performed in order to increase FDCA titer and productivity with whole cells of *P. putida* S12 pJT'hmfH.

In the initial batch phase, *P. putida*_pJT'hmfH was cultured on MM until the initial glycerol was depleted (OD600 ≈ 8) after 23.2 hours of fermentation. At this point the glycerol feed was started at a rate that allowed a biomass increase of approximately 0.45 g CDW/l/h. After 50.7 hours of fermentation, the glycerol feed was decreased to a rate that allowed a biomass increase of approximately 0.045 g CDW/l/h. After 123.4 hours of fermentation, the glycerol feed was increased to a rate that allowed a biomass increase of approximately 0.25 g CDW/l/h until the end of the fermentation. Over this period, a HMF feed was applied. The HMF feed started at a rate of 0.65 mmol/h/g CDW

after 26.7 hours of fermentation, leading to the accumulation of both HMF acid and FDCA. The HMF feed rate was decreased to 0.28 mmol/h/g CDW after 33.3 hours of fermentation, decreased further to 0.09 mmol/h/g CDW after 72.8 hours of fermentation and stopped after 117.4 hours of fermentation. The decreasing HMF feed led to a gradual decrease of the HMF acid concentration in the fermentor, while the FDCA concentration continued to increase. The fermentation was stopped when no more HMF acid could be detected. At this point 188 mmol of HMF was added to the fermentor, leading to the production of approximately 182 mmol FDCA (i.e., 97% efficiency) at a concentration of 30.8 g/l. Figure 7a shows the formation of biomass, HMF acid and FDCA in the fed-batch culture of *P. putida*_pJT'hmfH. Figure 7b shows the feed rates of glycerol and HMF of the same culture.

Example VIII

Purification of FDCA from fermentation broth

The solubility of FDCA at a pH of 0.5 was found to be around 0.4 g/l in water. Since this concentration remains in solution after precipitation, the increased titer obtained in example VIII leads to a much reduced loss of product from purification by precipitation.

After removal of cells by centrifugation (9500 x g for 15 min), 500 ml of the clarified broth was boiled for 3 minutes to precipitate proteins and centrifuged for 20 min at 9500 x g. Approximately 50 ml 96 % H₂SO₄ was added to the supernatant at 4 °C under continuous stirring until pH 0.5, in order to precipitate FDCA. The precipitate was recovered by centrifugation at 8228 x g for 20 min, washed once with 250 ml of water and centrifuged again at 8228 x g for 20 min. The resulting pellet was air-dried and then dissolved in approximately 1200 ml tetrahydrofuran (THF) at 30 °C. Upon removal of undissolved debris by filtration, the clarified THF solution was evaporated under vacuum at 50 °C until 11.8 g of dry FDCA powder remained with a high purity (>99%), which is 78% of the FDCA initially in the fermentor broth. If needed, the purification of FDCA can be further optimized using methods well known in the art.

Applicant's or agent's file reference number 27470-WO-PCT	International application No.
---	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description first mentioned on page 21 (approx) line 35	
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet <input type="checkbox"/>
Name of depositary institution Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH	
Address of depositary institution (including postal code and country) Inhoffenstraße 7B 38124 Braunschweig GERMANY	
Date of deposit August 19, 2009.	Accession Number DSM 22875
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
We inform you that the availability of the microorganism identified above, referred to Rule 13bis PCT, shall be effected only by issue of a sample to an expert nominated by the requester until the publication of the mention of grant of the national patent or, where applicable, for twenty years from the date of filing if the application has been refused, withdrawn or deemed to be withdrawn.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	
<input type="checkbox"/>	This sheet was received with the international application
Authorized officer	

For International Bureau use only	
<input type="checkbox"/>	This sheet was received by the International Bureau on:
Authorized officer	

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An isolated polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 70% or more sequence identity with SEQ ID NO: 3.
2. An isolated polynucleotide which comprises:
 - (a) the nucleotide sequence set out in SEQ ID NO: 4;
 - (b) a nucleotide sequence encoding a polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 70% sequence identity with SEQ ID NO: 3;
 - (c) a fragment of a nucleotide sequence as defined in (a) or (b) which is at least about 100 nucleotides in length; or
 - (d) a nucleotide sequence which is the reverse complement of a nucleotide sequence as defined in (a), (b) or (c)
3. A nucleic acid construct comprising the polynucleotide according to claim 2.
4. A vector incorporating a polynucleotide sequence according to claim 2 or a nucleic acid construct according to claim 3.
5. A cell comprising a polypeptide according to claim 1, a polynucleotide according to claim 2, a nucleic acid construct according to claim 3 or a vector according to claim 4.
6. A cell according to claim 5 wherein the cell is a bacterium chosen from the group of *Escherichia*, *Anabaena*, *Caulobacter*, *Gluconobacter*, *Rhodobacter*, *Pseudomonas*, *Paracoccus*, *Bacillus*, *Brevibacterium*, *Corynebacterium*, *Rhizobium* (*Sinorhizobium*), *Flavobacterium*, *Klebsiella*, *Enterobacter*, *Lactobacillus*, *Lactococcus*, *Methylobacterium*, *Staphylococcus* or *Streptomyces* genus; or *B. subtilis*, *B. amyloliquefaciens*, *B. licheniformis*, *B. punctis*, *B. megaterium*, *B. halodurans*, *B. pumilus*, *G. oxydans*, *Caulobacter crescentus* CB 15, *Methylobacterium extorquens*, *Rhodobacter sphaeroides*, *Pseudomonas putida*, *Paracoccus zeaxanthinifaciens*, *Paracoccus denitrificans*, *E. coli*, *C. glutamicum*, *Staphylococcus carnosus*, *Streptomyces lividans*, *Sinorhizobium*

melioti and *Rhizobium radiobacter* species.

7. A cell according to claim 5 wherein the cell is a yeast cell from the group consisting of the *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* genus; or *Kluyveromyces lactis*, *S. cerevisiae*, *Hansenula polymorpha*, *Yarrowia lipolytica* and *Pichia pastoris* species or a filamentous fungal cell from the group *Aspergillus*, *Chrysosporium*, *Penicillium*, *Talaromyces* or *Trichoderma* genus; or *Aspergillus niger*, *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus sojae*, *Aspergillus fumigatus*, *Talaromyces emersonii*, *Aspergillus oryzae*, *Chrysosporium lucknowense*, *Trichoderma reesei* or *Penicillium chrysogenum* species.
8. A method for the preparation of a polypeptide having oxidoreductase activity, which method comprises cultivating a cell according to any of claims 5 to 7 under conditions which allow for expression of said polypeptide and, optionally, recovering the expressed polypeptide.
9. A polypeptide obtainable by a method according to claim 8.
10. Process for the production of 2,5-furandicarboxylic acid (FDCA), wherein one or more furanic precursor of FDCA is converted to FDCA, by reaction with an oxidant in the presence of an oxidoreductase catalyst and optionally one or more coenzyme, wherein the oxidoreductase catalyst comprises a polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 45% sequence identity with SEQ ID NO: 3.
11. Process according to claim 10, wherein the furanic precursor of FDCA is chosen from the group chosen from the group consisting of 5-hydroxymethylfurfural (HMF), 2,5-dihydroxymethyl furan (HMF alcohol) and 5-hydroxymethyl-2-furancarboxylic acid (HMF acid), preferably the furanic precursor is HMF.
12. Process according to claim 10 or 11, wherein the precursor is HMF and HMF is obtained from one or more hexose sugars by heating in presence of acid, wherein preferably the one or more hexose sugars is obtained from biomass.
13. Process for the production of 5-hydroxymethyl-2-furancarboxylic acid (HMF acid) wherein one or more furanic precursor of HMF acid is converted to HMF acid by

reaction with an oxidant in the presence of an oxidoreductase catalyst and optionally one or more coenzyme cofactor, wherein the oxidoreductase catalyst comprises a polypeptide having oxidoreductase activity which polypeptide comprises an amino acid sequence having at least 45% sequence identity with SEQ ID NO: 3.

14. Process according to claim 13, wherein the furanic precursor of HMF acid is chosen from the group chosen from 5-hydroxymethylfurfural (HMF) and 2,5-dihydroxymethyl furan (HMF alcohol).

15. Process according to any one of claims 10 to 14, wherein the coenzyme is nicotinamide adenine dinucleotide (NAD⁺) and/or pyrroloquinoline quinolone (PQQ) and/or flavin adenine dinucleotide (FAD).

16. Process according to any one of claims 10 to 15 wherein the oxidoreductase catalyst is a cell free extract of a cell according to any one of claims 5 to 7.

17. Process according to any one of claims 10 to 16 wherein the oxidoreductase catalyst is a whole cell biocatalyst being a cell according to any one of claims 5 to 7.

18. Process for the production of a polymer from one or more monomers, wherein at least one of the monomers is FDCA produced in a process according to any one of claims 10 to 12 and 15 to 17.

19. FDCA produced by the process of any one of claims 10 to 12 and 15 to 17.

20. HMF acid produced by the process of any one of claims 13 to 17.

21. An isolated polypeptide according to claim 1; or an isolated polynucleotide according to claim 2; or a process according to claim 10 or claim 13, substantially as hereinbefore described with reference to the Examples and/or Figures.




Fig. 1




Fig. 2




Fig. 3A

Methylobacterium*radiotolerans* JCM2831*Mrad2831_*

Sp. 4-46

*M446_**nodulans* O RS2060*Mnod_****Acidiphilium****cryptum* JF-5*Acry_****Dinoroseobacter****shibae* DFL 12*Dshi_*

52166 40170 54476

3714 3715 3716

Fig. 3B




Fig. 3C




Fig. 3D




Fig. 4




Fig. 5




Fig. 6




Fig. 7A




Fig. 7B

eol f - seq
SEQUENCE LISTING

<110> DSM I P Asset s B. V.
 <120> POLYPEPTIDES HAVING OXIDOREDUCTASE ACTIVITY AND THEIR USES
 <130> 27470- WO- PCT
 <160> 4
 <170> Patent I n version 3. 5
 <210> 1
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic DNA

<400> 1
 cggaattcca catgacaagg ggagaccg 28

<210> 2
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic DNA

<400> 2
 cggaattcgc ttcggtcttc aactcggatg 30

<210> 3
 <211> 579
 <212> PRT
 <213> Cupriavidus basilensis

<400> 3

Met Asp Thr Pro Arg Glu Arg Phe Asp Tyr Val Ile Val Gly Gly Gly
 1 5 10 15

Ser Ala Gly Cys Val Leu Ala Asn Arg Leu Ser Gln Asp Pro Ala Ile
 20 25 30

Arg Val Ala Leu Ile Glu Ala Gly Val Asp Thr Pro Pro Asp Ala Val
 35 40 45

Pro Ala Glu Ile Leu Asp Ser Tyr Pro Met Pro Leu Phe Phe Gly Asp
 50 55 60

Arg Tyr Ile Trp Pro Ser Leu Gln Ala Arg Ala Val Ala Gly Gly Arg
 65 70 75 80

Ser Lys Val Tyr Glu Gln Gly Arg Val Met Gly Gly Gly Ser Ser Ile
 85 90 95

Asn Val Gln Ala Ala Asn Arg Gly Leu Pro Arg Asp Tyr Asp Glu Trp

eof - seq1

100

105

110

Ala	Ala	Ser	Gly	Ala	Ser	Gly	Trp	Ser	Trp	Gln	Asp	Val	Leu	Pro	Tyr
		115					120					125			
Phe	Arg	His	Leu	Glu	Arg	Asp	Val	Asp	Tyr	Gly	Asn	Ser	Pro	Leu	His
	130					135					140				
Gly	Ser	His	Gly	Pro	Val	Pro	Ile	Arg	Arg	Ile	Leu	Pro	Gln	Ala	Trp
145					150					155					160
Pro	Pro	Phe	Cys	Thr	Glu	Phe	Ala	His	Ala	Met	Gly	Arg	Ser	Gly	Leu
				165					170					175	
Ser	Ala	Leu	Ala	Asp	Gln	Asn	Ala	Glu	Phe	Gly	Asp	Gly	Trp	Phe	Pro
			180					185					190		
Ala	Ala	Phe	Ser	Asn	Leu	Asp	Asp	Lys	Arg	Val	Ser	Thr	Ala	Ile	Ala
		195					200					205			
Tyr	Leu	Asp	Ala	Asp	Thr	Arg	Arg	Arg	Ala	Asn	Leu	Arg	Ile	Tyr	Ala
	210					215					220				
Glu	Thr	Thr	Val	Arg	Lys	Leu	Val	Val	Ser	Gly	Arg	Glu	Ala	Arg	Gly
225					230					235					240
Val	Ile	Ala	Met	Arg	Ala	Asp	Gly	Ser	Arg	Leu	Ala	Leu	Asp	Ala	Gly
				245					250					255	
Glu	Val	Ile	Val	Ser	Ala	Gly	Ala	Leu	Gln	Ser	Pro	Ala	Ile	Leu	Met
			260					265					270		
Arg	Ala	Gly	Ile	Gly	Asp	Ala	Gly	Ala	Leu	Gln	Ala	Leu	Gly	Ile	Glu
		275					280					285			
Val	Val	Ala	Asp	Arg	Pro	Gly	Val	Gly	Arg	Asn	Leu	Gln	Asp	His	Pro
	290					295					300				
Ala	Leu	Thr	Phe	Cys	Gln	Phe	Leu	Ala	Pro	Gln	Tyr	Arg	Met	Pro	Leu
305					310					315					320
Ser	Arg	Arg	Arg	Ala	Ser	Met	Thr	Ala	Ala	Arg	Phe	Ser	Ser	Gly	Val
				325					330					335	
Pro	Gly	Gly	Glu	Ala	Ser	Asp	Met	Tyr	Leu	Ser	Ser	Ser	Thr	Arg	Ala
			340					345					350		
Gly	Trp	His	Ala	Leu	Gly	Asn	Arg	Leu	Gly	Leu	Phe	Phe	Leu	Trp	Cys
		355					360					365			
Asn	Arg	Pro	Phe	Ser	Arg	Gly	Gln	Val	Ser	Leu	Ala	Gly	Ala	Gln	Pro

eof - seq1

370

375

380

Asp Val Pro Pro Met Val Gu Leu Asn Leu Leu Asp Asp Gu Arg Asp
385 390 395 400

Leu Arg Arg Met Val Ala Gly Val Arg Lys Leu Val Gln Ile Val Gly
405 410 415

Ala Ser Ala Leu His Gln His Pro Gly Asp Phe Phe Pro Ala Thr Phe
420 425 430

Ser Pro Arg Val Lys Ala Leu Ser Arg Val Ser Arg Gly Asn Val Leu
435 440 445

Leu Thr Gu Leu Leu Gly Ala Val Leu Asp Val Ser Gly Pro Leu Arg
450 455 460

Arg Ser Leu Ile Ala Arg Phe Val Thr Gly Gly Ala Asn Leu Ala Ser
465 470 475 480

Leu Leu Thr Asp Gu Ser Ala Leu Gu Gly Phe Val Arg Gln Ser Val
485 490 495

Phe Gly Val Trp His Ala Ser Gly Thr Cys Arg Met Gly Ala His Ala
500 505 510

Asp Arg Ser Ala Val Thr Asp Ala Ala Gly Arg Val His Asp Val Gly
515 520 525

Arg Leu Arg Val Ile Asp Ala Ser Leu Met Pro Arg Leu Pro Thr Ala
530 535 540

Asn Thr Asn Ile Pro Thr Ile Met Leu Ala Gu Lys Ile Ala Asp Thr
545 550 555 560

Met Gln Ala Gu Arg Arg Ala Val Arg Pro Ala Ser Ser Gu Val Ala
565 570 575

His Pro Ser

<210> 4

<211> 1740

<212> DNA

<213> Cupriavidus basilensis

<400> 4

at ggat acgc cgagggagcg tttcgact ac gt gat tgttg gcggcggt c cgccggt tgc 60

gt act ggcca at cgcct gt c gcaggaccg gccat ccgcg t cgcgct gat cgaggcgggc 120

gt cgat acgc cgccggacgc tgt gccggcg gagat cct cg acagct at cc gat gccct t g 180

ttcttcggt g accggt at at ct ggccat cg ct gcaagccc gcgccgt ggc agggggcagg 240

eol f - seq1

t ccaaggt ct	acgagcaagg	gcgcgt cat g	ggcggcggct	ccagcat caa	cgt gcaggcg	300
gcaaaccgcg	ggct gccgcg	cgact acgat	gagt gggccg	cgt cgggcgc	gt ccggat gg	360
t cgt ggcagg	at gt gct gcc	gt at t t ccgc	cacct t gage	gcgat gt gga	t t acggcaac	420
agcccgt gc	acggcagcca	cggaccggt g	ccgat ccgcc	gcat cct gcc	gcaggct t gg	480
ccgccgt t ct	gcacggagt t	t gcgcacgcg	at gggccgca	gcggct t gt c	cgcgct ggcc	540
gaccagaacg	cggagt t cgg	cgat ggct gg	t t t ccggccg	cct t ct cgaa	cct ggat gac	600
aagcgggt t t	cgaccgcat	cgcct at ct c	gacgcggat a	cgcgccggcg	ggccaat ct g	660
cggat ct at g	ccgagacaac	ggg gcgcaag	ct cgt cgt at	ccggccggga	agcgct ggg	720
gt gat cgcca	t gcgggccga	t gggc gcgcg	ct ggcgct gg	acgccgggga	ggg cat cgt g	780
t ccgcgggcg	cct t gcagt c	gcccgccat c	ct gat gcgcg	cggggat cgg	cgacgccggc	840
gcgct gcagg	ccct cggcat	cgaggt cgt a	gccgaccgac	ccggcgt t gg	ccgcaat ct c	900
caggat cat c	ccgcgt gac	gt t ct gccag	t t cct cgcgc	cccagt accg	cat gccgct c	960
t cgcgccggc	gcgct agcat	gacggcggcg	cggg t ct cat	cgggggt gcc	aggt ggcgag	1020
gcgt cggaca	t gt acct gt c	cagt t ccaca	cgggcaggct	ggcat gact	cggg aat cgg	1080
ct cggcct ct	t ct t cct gt g	gt gcaat cgg	ccat t ct cgc	gcgggcagggt	gagcct t gcg	1140
ggagcccagc	cggat gt gcc	gccc at ggt g	gagct caacc	t gct cgacga	cgagcgggat	1200
ct gcggcgca	t ggt ggccgg	cgt acgcaag	t t ggt gcaga	t cgt ggggt gc	gt cggcct t g	1260
cat cagcat c	ccgggt gat t t	ct t ccccgct	acgt t t t cgc	cgcgcgt caa	ggcgct gage	1320
cgcgt gagcc	gcggcaat gt	gt t gct cacg	gagt t gct gg	gggcagt gct	t gat gt ct cg	1380
gggccgct gc	gcagaagcct	gat cgcgcgc	t t t gt cacgg	gcggcgcaaa	cct ggccagc	1440
ct gct gacgg	at gagt ccgc	gct agagggc	t t cgt gcgcc	agagcgt ct t	cgggggt ct gg	1500
cat gccagcg	gact t gccg	gat gggcgcg	cat gcggacc	ggagcgcgggt	gacggat gcg	1560
gcgggccgcg	t t cacgat gt	t ggcaggct g	cgcgt t at t g	acgcct ct ct	gat gccgcgg	1620
ct gccgacgg	ccaat accaa	cat ccccacc	at cat gct cg	cggaaaagat	t gccgacacc	1680
at gcaagccg	agcgccgcgc	ggg ccggccg	gcat cgagcg	aagt t gcca	t ccgagt t ga	1740